TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00098891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given orally
Study: NCT01790425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: to infuse water into colon to open the lumen for water infusion colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air colonoscopy
Study: NCT02502318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracotomy
Study: NCT03463187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT03352947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabrafenib
Description: 150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
Study: NCT00098891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given orally
Study: NCT02866591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mammography according to an auto-compression procedure
Study: NCT04326829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: QL1604, IV infusion
Study: NCT02866591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mammography according to a standard procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionary
Study: NCT00697411

Intervention type: OTHER
Intervention: Syndrome cause identification
Study: NCT02866591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionary
Study: NCT02822196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local Anesthesia using 1% Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local Anesthesia using 0.25% Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local Anesthesia using 0.25% Bupivacaine
Study: NCT00996424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Inhalation with N-Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Inhalation with normal saline solution
Study: NCT03468712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Description: Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
Study: NCT00578968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
Study: NCT03624855

Intervention type: OTHER
Intervention: Bone or joint infection due to Pseudomonas aeruginosa
Description: Description of bone or joint infection on implant due to Pseudomonas aeruginosa
Study: NCT03352947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
Study: NCT02329522

Intervention type: DEVICE
Intervention: Ultrasonic Cardiac Output Monitor
Description: An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow.

Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.

Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
Study: NCT02451306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: See information in arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See information in arm description.
Study: NCT01873339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
Study: NCT03635567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01873339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
Study: NCT02226991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Study: NCT03458143

Intervention type: DRUG
Intervention: Ketamine 150 ng/ml
Description: conscious sedation in TCI-mode
Study: NCT03635567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study: NCT03167060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active RhinoChill
Description: Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device.
Study: NCT03635567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study: NCT02633813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine hydrochloride 2%
Description: Topical application for two weeks
Study: NCT03635567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to pembrolizumab
Description: IV infusion
Study: NCT02612584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinhole Soft Contact Lens apply for presbyopia
Study: NCT02906306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Occupational Therapy
Description: 45 minutes 3 times per week 6 months in nursing homes (A and B)
Study: NCT03167060

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Rhinochill
Description: Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device.
Study: NCT01844596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral communication strategy
Description: Community Health Workers with an additional tailored behavioral communication strategy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral communication strategy, plus smartphone-based tool
Description: Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
Study: NCT02906306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Occupational Therapy
Description: 45 minutes 3 times per week 6 months in nursing homes (A and B)
Study: NCT04144517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa
Description: Nemvaleukin alfa IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa
Description: Nemvaleukin alfa IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.
Study: NCT03899428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV (intravenous infusion)
Study: NCT02162667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
Study: NCT03899428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Prescribed by physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Prescribed by physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Prescribed by physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Prescribed by physician.
Study: NCT03664544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg MCI-186 will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg MCI-186 will be administered intravenously over 60 minutes.
Study: NCT03632044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
Study: NCT02329522

Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
Study: NCT04933305

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic surgical procedure
Study: NCT03003143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin 500 MG
Study: NCT03568149

Intervention type: PROCEDURE
Intervention: assessment of pain symptoms at first medical examination
Description: First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.

Intervention type: PROCEDURE
Intervention: assessment of pain symptoms at first medical examination
Description: First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
Study: NCT02976805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L PegLyte + 15 mg bisacodyl
Description: Randomized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6L PegLyte + 15 mg bisacodyl
Description: Randomized
Study: NCT00933478

Intervention type: DEVICE
Intervention: Clay
Description: Small dime sized piece of clay.
Study: NCT04093453

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Description: Participant receive Placebo (Sodium Chloride)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Description: Participant receive Placebo (Sodium Chloride)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sodium Chloride)
Description: Participant receive Placebo (Sodium Chloride)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 1 hour exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Participant receive Sodium Propionate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Participant receive Sodium Propionate
Study: NCT02162667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
Study: NCT04497961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
Study: NCT04093453

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Participant receive Sodium Propionate
Study: NCT04649099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study: NCT02633813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® 2% (Naftifine hydrochloride 2%)
Description: Topical application for two weeks
Study: NCT01085474

Intervention type: OTHER
Intervention: 1
Description: In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
Study: NCT04175015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartie© sweet/candy
Description: one chocolate sweet/ chocolate candy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartie© sweet/candy
Description: one chocolate sweet/ chocolate candy
Study: NCT04339777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan test dose
Description: 0.8 mg/kg IV infusion over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan test dose
Description: 0.8 mg/kg IV infusion over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 40 mg/m2 IV infusion over 30 min once daily for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 40 mg/m2 IV infusion over 30 min once daily for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
Study: NCT01085474

Intervention type: OTHER
Intervention: 2
Description: The best intervention used in the pilot study will be chosen and included in the main study.
Study: NCT03141593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: liquid form, start weekly
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: liquid form, start monthly
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: solid form, start weekly
Description: Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D: solid form, start monthly
Description: Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
Study: NCT00611208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
Study: NCT05283278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine and probiotics
Description: Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given starting from birth to the 30th day of life for neonates in group C.